What is PT-141?
PT-141, now known in pharmaceutical contexts as bremelanotide, is a cyclic heptapeptide that acts as an agonist at melanocortin receptors — specifically MC3R and MC4R. Its origins trace to research on Melanotan II, an earlier melanocortin peptide studied for skin pigmentation. Researchers noticed that Melanotan II had significant effects on sexual arousal and carved out the relevant molecular activity into a more selective compound. That compound became PT-141, and eventually bremelanotide.
The “PT” designation stands for “peptide thymosin” in early laboratory nomenclature, though bremelanotide has no relationship to thymosin peptides. The nomenclature is a historical artifact.
What distinguishes PT-141 / bremelanotide from other sexual health medications is its mechanism. It does not target blood vessels. It targets the central nervous system pathways involved in sexual desire and motivation — specifically the melanocortin system in the hypothalamus and limbic structures. This is why it is sometimes described as working “upstream” of vascular-focused medications.
How does the melanocortin mechanism work?
The melanocortin system encompasses a family of peptides (alpha-MSH and related fragments) and five receptor subtypes (MC1R through MC5R). MC3R and MC4R are expressed throughout the central nervous system and are involved in a wide range of functions: energy homeostasis, mood, pain modulation, and sexual function.
MC4R in particular has been extensively studied for its role in sexual behavior. In animal models, MC4R agonism produces proerectile effects in males and facilitates sexual receptivity in females. The hypothalamic paraventricular nucleus (PVN), which has high MC4R expression, is thought to be a key site of bremelanotide’s action.
The practical implication of this mechanism is that bremelanotide can theoretically address desire that is neurologically mediated rather than vascular. For patients whose sexual dysfunction relates to low desire rather than physical arousal mechanics, this different pathway may be relevant in ways that PDE5 inhibitors are not.
Is PT-141 FDA approved, and for what indication?
In June 2019, the FDA approved bremelanotide injection (marketed as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by persistently low sexual desire that causes meaningful personal distress and is not attributable to relationship problems or medical/psychiatric comorbidity.
The approval was based on two Phase 3 randomized, double-blind, placebo-controlled trials (the RECONNECT studies) enrolling 1,247 premenopausal women with HSDD. The primary endpoints were change from baseline in sexual desire as measured by the Female Sexual Function Index (FSFI) desire subscale and change in distress as measured by the Female Sexual Distress Scale-Desire subscale. Results showed statistically significant improvements on both measures compared to placebo.
The approval is specific: Vyleesi is indicated for premenopausal women with HSDD. Postmenopausal women and men are outside the approved indication. Use in those populations would be off-label and based on more limited evidence.
PT-141 is the unusual peptide with a real regulatory story — an FDA approval pathway most compounds in this space never reach.
What does the evidence in men show?
Clinical interest in PT-141 / bremelanotide for men predates the HSDD indication. Earlier studies examined its effects on erectile function in men with psychogenic or organic erectile dysfunction, and on sexual desire in men more broadly.
A notable early study published in 2004examined intranasal PT-141 in men with erectile dysfunction, reporting improved erectile function scores compared to placebo. Subsequent work looked at the compound in men who did not respond adequately to PDE5 inhibitors — a population where a centrally acting mechanism is theoretically more relevant.
The male evidence base is smaller and less well-controlled than the HSDD dataset. No FDA-approved product exists for men, and the clinical use in men would be off-label. A clinician evaluating whether bremelanotide might be relevant to a male patient’s situation would be working from this more limited evidence base.
What is the safety profile and what are the side effects?
The RECONNECT trials give a clearer safety picture than exists for most gray-zone peptides. The most significant adverse effect is nausea, which was reported by approximately 40% of bremelanotide users in clinical trials, compared to 1–2%in the placebo group. This is dose-dependent and time-limited (typically resolving within an hour), but it is the primary reason patients discontinue.
Transient blood pressure elevation occurs in the hours following administration. Blood pressure typically peaks within approximately 12 minutes and returns toward baseline within 12 hours. Vyleesi is therefore contraindicated in patients with uncontrolled hypertension or cardiovascular disease, and clinicians are advised not to administer it within 24 hours of medications that rely on vasodilation (including nitrates, which are an absolute contraindication when combined with PDE5 inhibitors).
Focal hyperpigmentation (skin darkening, particularly on the face, gums, and breasts) has been reported with repeated use. This reflects the compound’s activity at MC1R, the melanocortin receptor involved in skin pigmentation. The prescribing information recommends no more than one dose per 24 hours and monitoring for pigmentation changes with repeated use.
How does PT-141’s compounding status affect access?
Because bremelanotide (Vyleesi) is an FDA-approved drug, the 503A compounding landscape for it is different from peptides that have no approved pharmaceutical equivalent. Compounding an FDA-approved drug is generally only permitted under specific circumstances, such as meeting a clinical need that the approved formulation cannot satisfy.
At PepScribe, PT-141 / bremelanotide is classified as a gray-zone peptide. It is not available for direct ordering through the platform. If sexual desire or function concerns are part of your health goals, the appropriate path is through a clinician consultation. A licensed clinician can evaluate your specific history, identify what is appropriate in your situation, and prescribe accordingly — which may or may not include bremelanotide depending on your circumstances, history, and applicable pharmacy options.
Frequently asked questions
What is PT-141?
PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist peptide. Unlike PDE5 inhibitors (sildenafil, tadalafil) that work through vascular mechanisms, PT-141 acts centrally through melanocortin receptors in the brain that regulate sexual desire.
Is PT-141 FDA approved?
Yes. The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the only FDA-approved indication. Off-label use in men and postmenopausal women is studied but not an approved use.
How is PT-141 administered?
The FDA-approved Vyleesi formulation is a subcutaneous auto-injector used on-demand approximately 45 minutes before anticipated sexual activity. Nasal spray formulations have also been studied in clinical trials.
What are the common side effects of PT-141?
The most common adverse effects reported in Vyleesi trials include nausea (affecting a substantial proportion of users), flushing, and transient blood pressure elevation in the hours following administration. Nausea is dose-dependent and the most common reason for discontinuation.
How does PT-141 differ from medications like Viagra?
PDE5 inhibitors like sildenafil increase blood flow to genital tissue and primarily address the physical mechanics of erectile or arousal function. PT-141 works centrally — it activates melanocortin receptors in the brain that are involved in sexual desire motivation, not vascular mechanics. The two mechanisms target different aspects of sexual function.
Is PT-141 available through PepScribe?
PT-141 is a gray-zone peptide at PepScribe. It is not available for direct online ordering. If your goals relate to sexual desire or function, a clinician consultation through PepScribe's Sexual Vitality program is the appropriate starting point — the clinician will evaluate your history and recommend what is appropriate.